Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating children
who have relapsed or refractory rhabdomyosarcoma.